Rallybio Corp
RLYB · Pharmaceutical Preparations · 5.3M shares · -40%/yr ↓ buyback · EDGAR filings ↗
Reference price $13.98 · est. market cap ~$74M — last insider purchase, 2026-05-19 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — rare-disease clinical, very cash-rich.
Strengths
- Liquidity — current ratio 14.5 (89th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -1046.4%)
- Insider buyingInsider buying — 14 open-market buy(s) by 1 insider(s) (~$4M, last 6mo) Form 4 ↗
- Buying back stockNet buyback — share count -40%/yr over 3y
- Pending merger” Risks Related to the Merger Failure to complete, or delays in completing, the proposed Merger with Candid could materially and adversely affect our results of operations, business, financial r
- Notable holderHeld by 3 notable fund(s): FMR LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-3853.6%
Net margin
-1046.4%
Return on equity
-15.5%
Return on assets
-14.4%
Revenue growth (QoQ)
-4.5%
Current ratio
14.5×
EBITDA
-$33M
Tangible book value
$58M
Cash & investments
$55M
Stock comp / revenue
619.3%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-19 | ADAR1 Capital Management, LLC | Buy | 10K | $13.98 |
| 2026-05-19 | ADAR1 Capital Management, LLC | Buy | 200 | $13.80 |
| 2026-05-18 | ADAR1 Capital Management, LLC | Buy | 6.0K | $13.98 |
| 2026-05-15 | ADAR1 Capital Management, LLC | Buy | 100 | $13.80 |
| 2026-05-15 | ADAR1 Capital Management, LLC | Buy | 200 | $13.95 |
| 2026-05-13 | ADAR1 Capital Management, LLC | Buy | 4.1K | $13.80 |
| 2026-05-13 | ADAR1 Capital Management, LLC | Buy | 75K | $14.00 |
| 2026-05-12 | ADAR1 Capital Management, LLC | Buy | 800 | $13.83 |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 25K | $14.00 |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 5.1K | $14.00 |
| 2026-05-11 | ADAR1 Capital Management, LLC | Buy | 20K | $14.00 |
| 2026-05-05 | ADAR1 Capital Management, LLC | Buy | 35K | $14.00 |
| 2026-05-04 | ADAR1 Capital Management, LLC | Buy | 3.9K | $13.90 |
| 2026-05-04 | ADAR1 Capital Management, LLC | Buy | 117K | $13.97 |
| 2026-02-23 | Lieber Jonathan I | Sell | 789 | $5.06 |
| 2026-02-18 | Lieber Jonathan I | Grant | 2.5K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-01 | Material agreement3.025.01Exec/director changeReg FDExhibits | filing ↗ |
| 2026-05-04 | 1.02Exhibits | filing ↗ |
| 2026-03-31 | Exec/director change | filing ↗ |
| 2026-03-02 | Material agreement3.025.01Exec/director changeReg FDExhibits | filing ↗ |
| 2026-01-29 | 5.03Shareholder voteExhibits | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
| 2025-08-29 | Delisting noticeExhibits | filing ↗ |
| 2025-08-07 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-01 | 2026-05-31 | 0001193125-26-249790 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001628280-26-034580 ↗ |
| 8-K | 2026-05-04 | 2026-05-03 | 0001193125-26-202601 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001628280-26-022385 ↗ |
| 10-K | 2026-03-16 | 2025-12-31 | 0001628280-26-018261 ↗ |
| 8-K | 2026-03-02 | 2026-03-01 | 0001193125-26-084444 ↗ |
| 8-K | 2026-01-29 | 2026-01-26 | 0001739410-26-000010 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001739410-25-000132 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001739410-25-000131 ↗ |
| 8-K | 2025-08-29 | 2025-08-26 | 0001193125-25-192749 ↗ |
| 8-K | 2025-08-07 | 2025-08-07 | 0001739410-25-000108 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0001739410-25-000112 ↗ |